About this trial
The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patients' immune response to a common viral infection known as cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.
Eligibility criteria
Qualifiers
Received a lung transplant, or multi-organ transplant involving a lung at NYU Langone Health
Pre-existing serological immunity to CMV (R+)
Able and willing to provide informed consent
Disqualifiers
Anti-thymocyte globulin induction immunosuppression
Perioperative desensitization
Pregnant or breastfeeding women
Trial design
Treatments tested in this trial
- Cytomegalovirus T Cell Immunity Panel (CMV-TCIP)
- Donor-Derived Cell-Free DNA (dd-cfDNA) Assay
- Valganciclovir
Treatment groups
Sponsors and collaborators
NYU Langone Health
Lead sponsor
Viracor Eurofins
Collaborator